Deals Of The Week: Sun/Dusa; Pfizer/Alliance For Lupus Research; Merck/Regenstrief Institute
Executive Summary
Preclinical protein platform play Envoy got taken out by Takeda last week for up to $140 million. That magical “up to” typically hides a multitude of sins, but here that may not be the case.
You may also be interested in...
Pfizer, Alliance For Lupus Research To Co-Fund Translational Projects
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.